黄连素伍用谷维素对Ⅱ型糖尿病患者肠道菌群的影响

摘要

目的 探讨黄连素伍用谷维素对Ⅱ型糖尿病患者肠道菌群的影响.方法 研究对象为130例Ⅱ型糖尿病患者,其中未服用黄连素及谷维素治疗的患者47例,服用黄连素伍用谷维素治疗的患者43例,仅服用谷维素的患者40例.观察三组患者的临床表现、粪便外观性状,并采用直接涂片革兰染色法镜检各组粪便的菌落数及球杆比.结果 未治疗组粪便菌落数和球杆比分别为(59 560±855)和(1.03±0.4);黄连素伍用谷维素治疗组粪便菌落数和球杆比分别为(60 490±919)和(1.04±0.5);谷维素治疗组粪便菌落数和球杆比分别为(59 211±155)和(1.03±0.2).后两组与第一组(对照组)相比菌落数与球杆比均无明显差异(P>0.05).大便的物理性状三者亦无明显差异.临床观察黄连素伍用谷维素组偶见一过性大便次数增多、腹胀,均未作处理自愈,未见发热.结论 黄连素伍用谷维素对Ⅱ型糖尿病患者肠道菌群无显著性影响.%Objective To investigate the effect of berberine-oryzanol on intestinal mircoflora in type II diabetes. Methods We studied 130 type II diabetes patients,which were divided into three groups:the untreated group( 47 cases ),the berberine-oryzanol treated group ( 43 cases )and oryzanol treated group ( 40 cases ). The clinical manifestations and feces morphology of three groups were observed. All fe-ces samples were performed direct smear and Gram staining to caculate their bacteria colonies and C/B value. Results The respective bacteria colonies and C/B value of three groups were 59 560 ±855 and 1. 03 ±0. 4,60 490 ±919 and 1. 04 ±0. 5,59 211 ± 155 and 1.03 ±0.2. There were no significant differences between the latter two groups and the first group( the control group )in the number of intestinal bacteria colonies and C/B value. Increasing frequency of defecation and abdominal distension were observed occasionally in some berberine-oryzanol treated cases, which was relieved spontaneously without being treated, and no fever was observed in these cases. Conclusion Berberine-oryzanol had no significant effect on intestinal mircoflora of people with diabetes.